Study of AK117 with azacitidine and venetoclax for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called AK117 combined with two standard treatments (azacitidine and venetoclax) for people with acute myeloid leukemia (AML). The goal is to see if this combination is safe and effective in treating the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of acute myeloid leukemia (AML).
- You must be able to perform daily activities (with some help if needed) and have a life expectancy of at least 12 weeks.
- Your organs (like liver and kidneys) must be functioning well enough.
- If you can become pregnant or father a child, you must agree to use effective birth control during the study and for 120 days after the last dose.
- You cannot have certain other types of leukemia or have had a stem cell transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests whether adding a new medicine (IPN60340) to the usual two-drug combo (azacitidine and venetoclax) helps people with newly diagnosed acute myeloid leukemia (AML) who are not able to receive intensive chemotherapy. It may offer a more effective treatment option for those who cannot tolerate stronger chemotherapy.
Hear when a new ACUTE MYELOID LEUKEMIA; AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.